90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antibodies, Monoclonal
  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Pancreatic Neoplasms
  • Radioimmunotherapy
  • Radiopharmaceuticals
  • Yttrium Radioisotopes

abstract

  • Clinical studies of (90)Y-clivatuzumab tetraxetan combined with low-dose gemcitabine appear feasible in metastatic pancreatic cancer patients beyond 2nd line and a Phase III trial of this combination is now underway in this setting.

authors

publication date

  • June 7, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2015.06.119

PubMed ID

  • 26187510

Additional Document Info

start page

  • 1857

end page

  • 64

volume

  • 51

number

  • 14